期刊文献+

再析绝经妇女激素替代治疗

Hormone therapy for postmenopausal women
下载PDF
导出
摘要 近60年来HT(Hormone therapy)的应用已在很多国家展开,并已成为当前研究绝经后妇女生活质量和健康状态的热点,对HT的安全性,医患双方都极为关注,在临床医生中仍有不同观点,甚至仍然是个争论的焦点。我们今天讨论的重点不再是绝经后妇女该不该用HT,而是HT可以预防什么病,谁需要用HT、谁能用HT以及如何有效、安全地使用HT。理想的HT应该是能有效缓解绝经前后出现的症状,预防泌尿生殖器官萎缩、预防骨丢失加速、保护心血管、促进心理健康,提高社会交往能力;无不规则的阴道出血;不增加癌的危险。对所有需要用又没有禁忌证的妇女给予规范化、个体化、系统化的HT治疗以及定期监测,可以保证所有使用HT的妇女冒最小的风险得到最大的利益。 Hormone therapy(HT) has been used in many countries for 60 years and become the focus of living quality and health status in postmenopausal women. The safety of HT is still a subject of debate. Now what we discuss is who need HT,who can use HT as well as how to use HT. The ideal HT can relieve the symptoms of menopause effectively,including prevention the atrophy of uropoiesis and reproduction organs,prevention bone loss,promotion mental health,improvement social skills,as well as no vaginal bleeding,and no increased cancer risk. If those who need HT with no contraindications can be given standardized,individualized and systematized treatment of HT and monitored regularly,they can get the biggest benefit with minimal risk.
出处 《中国骨质疏松杂志》 CAS CSCD 2009年第4期308-310,共3页 Chinese Journal of Osteoporosis
关键词 性激素替代治疗 绝经后 激素 Hormone therapy(HT) Postmenopausal Hormone
  • 相关文献

参考文献8

  • 1张以文.重新认识绝经妇女长期性激素补充治疗的利弊[J].中华妇产科杂志,2003,38(8):487-488. 被引量:9
  • 2赖爱鸾,姜桂英,林守清,高青.激素替代治疗5年安全性分析[J].中国实用妇科与产科杂志,2004,20(1):53-54. 被引量:14
  • 3Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol. 2008, 51 (3) :564-580.
  • 4Martin KA, Manson JE. Approach to the patient with menopausal symptoms. J Clin Endocrinol Metab, 2008, 93 (12) :4567-4575.
  • 5刘春梅,徐苓.维生素K_2及其与性激素联合应用对去卵巢大鼠骨的影响[J].中国骨质疏松杂志,2008,14(8):537-542. 被引量:1
  • 6Christante D, Pommier S, Garreau J, et al. Improved breast cancer survival among hormone therapy users is durable after 5 years of additional follow-up. Am J Surg, 2008,196(4) :505-511.
  • 7All I, James T, Meston N, et al. Age and hormone therapy as factors influencing androgen levels in the postmenopausal female. Clin Chem Lab Med, 2009,47(2) :202-207.
  • 8Hachul H, Bittencourt LR, Andersen ML, et al. Effects of hormone therapy with estrogen and/or progesterone on sleep pattern in postmenopausal women. Int J Gynaecol Obstet, 2008,103 (3) : 207- 212.

二级参考文献22

  • 1[1]Palin SI,Kumar S,Stuedee DW,et al.Hormone replacement therapy for menopausal women with diabetes.Diab Obesity Metab,2001,3(3):187-192
  • 2[2]Writing Group for the PEPI Trial.Effects of hormone replacement therapy on endometrial histology in postmenopausal women:the postmenopausal estrogen/progestin intervention(PEPI)trial.JAMA,1996,275(5):370-376
  • 3[3]Ahmed M,Raafat PD,Lorne J,et al.Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model.Am J Obstet Gynecol,2001,184(2):340-349
  • 4[4]Compel M,Siromachkova A,Lombet D,et al.The effects of Tibolone on proliferation differentiation and apoptosis in normal breast cell.Gynecol Endocrin,1997,11(suppl):77-79
  • 5Carbonarea L, Valentia M, Bertoldoa F,et al. Bone microarchitecture evaluated by histomorphometry. Micron, 2005,36 : 609-616.
  • 6Scholz-Ahrens KE, Bohme P, Schrezenmeir J, et al. Vitamin K deficiency affects calcium retention, bone mineralization and Apb in growing and ovariectomized rats. Osteoporosis Int, 1996,6:S141.
  • 7Michelle M, Aixu S, Changcheng Zhou, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem,2003,278(45) :43919-43927.
  • 8Ichikawa T, Hofie-lnoue K, Ikeda K. Steroid and Xenobiotic Receptor SXR Mediates Vitamin KE-activated Transcription of Extraeellular Matrix-related Genes and Collagen Accumulation in Osteoblastic Cells.J Bio Chem,2006,281(25) : 16927-16934.
  • 9Urayama S, Kawakami A, Nakashima T, et al. Effect of Vitamin K2 on osteoblast apoptosis: Vitamin K2 inhibits apoptotic cell death of human osteoblasts induced by Fas, proteasome inhibitor, etoposide, and stanrosporine.J Lab Clin Med,2000, 136(3):181-193.
  • 10Hiruma Y. Nakahama K, Fujita H, et al. Vitamin K2 and geranylgeraniol, its side chain component, inhibited osteoclast formation in a different manner. Biochem Biophy Res Commu, 2004, 314:24-30.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部